Clinical trial NCT05790057 - References

Liver Steatoses — Subclinical Cardiovascular Changes in NAFLD Patient (Predictive Value of Speckle Tracking Echocardiography )

Citation(s)

•   Anstee QM, Mantovani A, Tilg H, Targher G
  Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2018 Jul;15(7):425-439. doi: 10.1038/s41575-018-0010-0.
•   Kasper P, Martin A, Lang S, Kutting F, Goeser T, Demir M, Steffen HM
  NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021 Jul;110(7):921-937. doi: 10.1007/s00392-020-01709-7. Epub 2020 Jul 21.
•   Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, Yilmaz Y, Czernichow S, Zheng MH, Wong VW, Allison M, Tsochatzis E, Anstee QM, Sheridan DA, Eddowes PJ, Guha IN, Cobbold JF, Paradis V, Bedossa P, Miette V, Fournier-Poizat C, Sandrin L, Harrison SA
  FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020 Apr;5(4):362-373. doi: 10.1016/S2468-1253(19)30383-8. Epub 2020 Feb 3. Erratum In: Lancet Gastroenterol Hepatol. 2020 Apr;5(4):e3.
•   Oeda S, Tanaka K, Oshima A, Matsumoto Y, Sueoka E, Takahashi H
  Diagnostic Accuracy of FibroScan and Factors Affecting Measurements. Diagnostics (Basel). 2020 Nov 12;10(11):940. doi: 10.3390/diagnostics10110940.
•   Pathik P, Ravindra S, Ajay C, Prasad B, Jatin P, Prabha S
  Fibroscan versus simple noninvasive screening tools in predicting fibrosis in high-risk nonalcoholic fatty liver disease patients from Western India. Ann Gastroenterol. 2015 Apr-Jun;28(2):281-286.
•   Zamirian M MD, Samiee E MD, Moaref A MD, Abtahi F MD, Tahamtan M MD
  Assessment of Subclinical Myocardial Changes in Non-Alcoholic Fatty Liver Disease: A Case-Control Study Using Speckle Tracking Echocardiography. Iran J Med Sci. 2018 Sep;43(5):466-472.

Subclinical Cardiovascular Changes in Patient With Non Alcoholic Fatty Liver Disease (Predictive Value of Speckle Tracking Echocardiography )

Details for clinical trial NCT05790057